📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: CG Oncology

1.1 - Company Overview

CG Oncology Logo

CG Oncology

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.

Products and services

  • BOND-003: Leads a Phase 3 monotherapy study of Cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Cretostimogene grenadenorepvec: An investigational oncolytic immunotherapy engineered to treat BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), currently progressing through clinical trials
  • PIVOT-006: Conducts a Phase 3 trial assessing Cretostimogene grenadenorepvec for the treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to CG Oncology

MOMA Therapeutics Logo

MOMA Therapeutics

HQ: United States Website
  • Description: Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MOMA Therapeutics company profile →
Favrille Logo

Favrille

HQ: United States Website
  • Description: Provider of targeted immunotherapies, focused on research, development and commercialization for the treatment of cancer and other diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Favrille company profile →
Linnaeus Therapeutics Logo

Linnaeus Therapeutics

HQ: United States Website
  • Description: Provider of development-stage cancer therapeutics, including LNS8801, an orally bioavailable, highly specific G protein-coupled estrogen receptor (GPER) agonist that depletes c-Myc protein levels, shows antitumor activities in preclinical cancer models, and is being tested in clinical trials as a monotherapy and with pembrolizumab.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Linnaeus Therapeutics company profile →
2seventy bio Logo

2seventy bio

HQ: United States Website
  • Description: Provider of immuno-oncology cell therapies, discovering and developing cancer treatments, including ABECMA (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma developed in collaboration with Bristol Myers Squibb; leveraging expertise in cancer cell biology, genetics, and the immune response to advance its pipeline.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full 2seventy bio company profile →
Mainz Biomed Logo

Mainz Biomed

HQ: Germany Website
  • Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mainz Biomed company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for CG Oncology

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to CG Oncology

2.2 - Growth funds investing in similar companies to CG Oncology

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for CG Oncology

4.2 - Public trading comparable groups for CG Oncology

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to CG Oncology

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About CG Oncology

What does CG Oncology do?

CG Oncology is a provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.

Who are CG Oncology's competitors?

CG Oncology's competitors and similar companies include MOMA Therapeutics, Favrille, Linnaeus Therapeutics, 2seventy bio, and Mainz Biomed.

Where is CG Oncology headquartered?

CG Oncology is headquartered in United States.

How many employees does CG Oncology have?

CG Oncology has 1,000 employees 🔒.

When was CG Oncology founded?

CG Oncology was founded in 2010 🔒.

What sector and industry vertical is CG Oncology in?

CG Oncology is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for CG Oncology

Who are the top strategic acquirers in CG Oncology's sector and industry

Top strategic M&A buyers and acquirers in CG Oncology's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for CG Oncology?

Top strategic M&A buyers groups and sectors for CG Oncology include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in CG Oncology's sector and industry vertical

Which are the top PE firms investing in CG Oncology's sector and industry vertical?

Top PE firms investing in CG Oncology's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in CG Oncology's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in CG Oncology's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in CG Oncology's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to CG Oncology include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in CG Oncology's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for CG Oncology?

The key public trading comparables and valuation benchmarks for CG Oncology include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for CG Oncology for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for CG Oncology with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in CG Oncology's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for CG Oncology with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in CG Oncology's' sector and industry vertical?

Access recent funding rounds and capital raises in CG Oncology's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for CG Oncology